Skip to content
OpenCapital
Get started

BioCryst Pharmaceuticals BCRX Weighted-Average Discount Rate - Finance Leases

Weighted-Average Discount Rate - Finance Leases at other companies

L3Harris Technologies logo
L3Harris TechnologiesLHX
4.2%-0.2pp
Griffon logo
GriffonGFF
7.3%+0.6pp
Belden logo
BeldenBDC
4.8%-0.1pp
American Healthcare REIT logo
American Healthcare REITAHR
11.3%+0.5pp
BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
9.9%+0.8pp
Center Bancorp logo
Center BancorpCNOB
6%0.0pp

Other financials

Income statement

See full
Revenue$156.4M+7.5%
Gross profit$151.0M+7.1%
Operating income-$701.6M-3,405%
Net income-$721.8M-2,255,763%
EPS (diluted)-$2.98—

Balance sheet

See full
Cash & equivalents$173.4M+62.2%
Total debt$411.8M+24.7%
Total equity-$553.8M-22.6%
Total assets$465.1M-3.1%

Cash flow

See full
Operating cash flow-$61.8M-125%
CapEx$403.0K+182%
Free cash flow-$62.2M-125%

Valuation

See full
Market cap$2.37B+52.3%
Enterprise value$2.6B+46.7%
P/S2.7×-0.4×

Profitability

See full
Gross margin97.8%+0.8pp
Operating margin-43.1%-49.7pp
Net margin-51.7%-69.7pp
FCF margin35%—

Returns & leverage

See full
Return on equity-882.8%—
Debt / equity0.1×—
Current ratio1.9×-1.0×

Where this comes from

Reported directly by BioCryst Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent.

The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioCryst Pharmaceuticals's weighted-average discount rate - finance leases.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is BioCryst Pharmaceuticals's weighted-average discount rate - finance leases?
BioCryst Pharmaceuticals (BCRX) reported weighted-average discount rate - finance leases of $0.1 in Q1 2026.
How has BioCryst Pharmaceuticals's weighted-average discount rate - finance leases changed year-over-year?
BioCryst Pharmaceuticals's weighted-average discount rate - finance leases increased by 8.2% year-over-year, from $0.09 to $0.1.
What is the long-term trend for BioCryst Pharmaceuticals's weighted-average discount rate - finance leases?
Over 2 years (2023 to 2025), BioCryst Pharmaceuticals's weighted-average discount rate - finance leases has grown at a 14.4% compound annual growth rate (CAGR), from $0.07 to $0.1.